Active Recombinant Human ANGPT2 Protein, His-tagged, Biotinylated

Cat.No. : ANGPT2-158H
Product Overview : Recombinant Human ANGPT2(Tyr19-Phe496) fused with His tag at C-terminal was expressed in NS0, Biotinylated.
  • Specification
  • Gene Information
  • Related Products
Description : Angiopoietin-2 (Ang-2; also ANGPT2) is a secreted glycoprotein that plays a complex role in angiogenesis and inflammation. Mature human Ang-2 is 478 amino acids (aa) in length. It contains one coiled-coil domain (aa 166-248) that mediates multimerization, and a C-terminal fibrinogen-like domain (aa 275-495) that mediates receptor binding. Under reducing conditions, secreted monomeric Ang-2 is 65-66 kDa in size. Under non-reducing conditions, both natural and recombinant Ang-2 form 140 kDa dimers, 200 kDa trimers, and 250-300 kDa tetramers and pentamers. Alternative splicing generates a short isoform that lacks 52 amino acids (aa) preceding the coiled-coil domain. Mature human Ang-2 shares 86% aa sequence identity with mouse and rat Ang-2. Ang-2 is widely expressed during development, but it is restricted postnatally to highly angiogenic tissues such as the placenta, ovaries, and uterus. It is particularly abundant in vascular endothelial cells (EC) where it is stored in intracellular Weibel-Palade bodies. Both Ang-2 and the related Angiopoietin-1 (Ang-1) are ligands for the receptor tyrosine kinase Tie-2. While Ang-1 is a potent Tie-2 agonist, Ang-2 may act as either a Tie-2 antagonist or agonist, depending upon its state of multimerization. The higher the order of oligomer, the more effective Ang-2 becomes as a Tie-2 agonist. The short isoform appears to block the binding of either Ang-1 or full-length Ang-2 to Tie-2. Ang-2 functions as a pro-angiogenic factor, although it can also induce EC death and vessel regression. Upon its release from quiescent EC, it regulates vascular remodeling by promoting EC survival, proliferation, and migration and destabilizing the interaction between EC and perivascular cells. Ang-2 is required for postnatal vascular remodeling, and it cooperates with Ang-1 during lymphatic vessel development. It mediates the up-regulation of ICAM-1 and VCAM-1 on EC, which facilitates the adhesion of leukocytes during inflammation. Ang-2 is up-regulated in both the endothelium and tumor cells of several cancers as well as in ischemic tissue. Its direct interaction with Integrins promotes tumor cell invasion. Ang-2 also promotes the neuronal differentiation and migration of subventricular zone progenitor cells.
Source : Mammalian cells
Species : Human
Tag : His
Predicted N Terminal : Tyr19
Form : Lyophilized from a 0.2 μm filtered solution in MOPS, NaCl, CHAPS and PEG with BSA as a carrier protein.
Bio-activity : Measured by its ability to activate Tie-2 in C6 rat glial cells transfected with human Tie-2. 0.2 μg/mL of Biotinylated Recombinant Human Angiopoietin-2 significantly induces phosphorylation of human Tie-2.
Molecular Mass : 56 kDa (unlabeled)
Protein length : Tyr19-Phe496
Endotoxin : <0.10 EU per 1 μg of the protein by the LAL method.
Purity : >95%, by SDS-PAGE with silver staining
Notes : Structure / Form: Oligomer, biotinylated via sugar residues
Storage : Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile
Reconstitution : Reconstitute at 100 μg/mL in PBS.
Gene Name : ANGPT2 angiopoietin 2 [ Homo sapiens ]
Official Symbol : ANGPT2
Synonyms : ANGPT2; angiopoietin 2; angiopoietin-2; Ang2; ANG-2; Tie2-ligand; angiopoietin-2B; angiopoietin-2a; ANG2; AGPT2;
Gene ID : 285
mRNA Refseq : NM_001118887
Protein Refseq : NP_001112359
MIM : 601922
UniProt ID : O15123

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.


  • Q&As
  • Reviews

Q&As (15)

Ask a question
Are there any potential side effects or risks associated with ANGPT2 inhibitors? 12/14/2022

Like any other therapeutic agent, ANGPT2 inhibitors may have side effects and risks. Common side effects reported in clinical trials include fatigue, headache, gastrointestinal disturbances, and hypertension. However, the specific side effects and risks may vary depending on the individual drug and its mechanism of action. It is important to consult with healthcare professionals and closely monitor patients during treatment to manage any potential adverse effects.

Can ANGPT2 inhibitors be used in combination with other therapies? 06/14/2022

Yes, ANGPT2 inhibitors can be used in combination with other therapies. Combining ANGPT2 inhibitors with other anti-angiogenic agents, chemotherapy, or immunotherapy may have synergistic effects and enhance treatment outcomes. Additionally, they may be combined with conventional treatments in diseases where ANGPT2 is implicated in disease progression or resistance to therapy. Clinical trials are ongoing to evaluate the safety and efficacy of these combination therapies.

Are there any inhibitors or activators of ANGPT2? 04/21/2021

Several compounds have been identified as inhibitors of ANGPT2. These include antibodies that specifically target ANGPT2, as well as small molecule inhibitors that interfere with its activity. In contrast, there are no known activators of ANGPT2 identified to date.

Are there natural compounds or dietary factors that can modulate ANGPT2 levels? 02/19/2020

Some studies suggest that certain natural compounds or dietary factors can modulate ANGPT2 levels. For example, green tea catechins, resveratrol, and curcumin have demonstrated potential in reducing ANGPT2 expression or activity in preclinical studies. However, more research is needed to determine their efficacy and safety in clinical settings.

Are there any genetic or epigenetic factors that regulate ANGPT2 expression? 08/13/2019

Yes, ANGPT2 expression is regulated by various genetic and epigenetic factors. Single nucleotide polymorphisms (SNPs) in the ANGPT2 gene have been associated with altered ANGPT2 expression levels and susceptibility to certain diseases. Additionally, epigenetic modifications, such as DNA methylation and histone modifications, can also regulate ANGPT2 expression by influencing the accessibility of the gene for transcription.

What are the challenges and future directions in the development and use of ANGPT2 inhibitors? 05/27/2019

One of the challenges in the development and use of ANGPT2 inhibitors is identifying the patient populations that would benefit most from this therapy. Understanding the precise mechanisms of ANGPT2 in different diseases and identifying reliable biomarkers for patient selection are important areas of future research.

What are the potential therapeutic applications of ANGPT2 inhibitors? 03/25/2019

ANGPT2 inhibitors have shown promise in various therapeutic applications. In cancer, blocking ANGPT2 can help normalize tumor blood vessels, improve drug delivery to the tumor, and enhance the effectiveness of anti-cancer therapies. Additionally, ANGPT2 inhibitors may also have potential in the treatment of other diseases involving abnormal angiogenesis, such as age-related macular degeneration, diabetic retinopathy, and inflammatory disorders.

What role does ANGPT2 play in cancer? 10/19/2018

In cancer, ANGPT2 is often upregulated and contributes to tumor angiogenesis and progression. It promotes vessel destabilization, allowing for the formation of leaky and irregular blood vessels within tumors. This abnormal vasculature can support tumor growth, metastasis, and resistance to therapies.

Are there ongoing clinical trials targeting ANGPT2 in cancer or other diseases? 07/05/2018

Yes, there are ongoing clinical trials investigating the therapeutic potential of targeting ANGPT2 in cancer and other diseases. These trials evaluate the efficacy and safety of ANGPT2 inhibitors either alone or in combination with other treatments. These studies aim to elucidate whether blocking ANGPT2 can have clinical benefits, such as inhibiting tumor growth, improving patient outcomes, or overcoming therapy resistance.

Can ANGPT2 be used as a biomarker in diseases? 06/15/2018

ANGPT2 has been explored as a potential biomarker in various diseases, including cancer, cardiovascular diseases, and sepsis. Elevated levels of ANGPT2 have been associated with disease progression and poor prognosis in some cases. However, further research is still needed to establish its clinical utility as a diagnostic or prognostic biomarker.

How is ANGPT2 involved in inflammation and immune responses? 08/15/2017

ANGPT2 plays a role in inflammation and immune responses by promoting vascular leakiness and enhancing the recruitment of immune cells to the site of inflammation. It is produced by immune cells, such as macrophages and neutrophils, in response to inflammatory stimuli. ANGPT2 can disrupt endothelial integrity, facilitating the extravasation of immune cells and contributing to the inflammatory process.

Are there any therapeutic strategies aimed at restoring the balance between ANGPT1 and ANGPT2? 05/07/2017

Yes, some therapeutic strategies aim to restore the balance between ANGPT1 and ANGPT2. These strategies include the administration of exogenous ANGPT1 or ANGPT2 inhibitors to regulate angiogenesis and vascular stability. The goal is to promote a more balanced and controlled angiogenic response, which may have therapeutic benefits in various diseases characterized by aberrant angiogenesis.

Are there any ongoing clinical trials investigating the use of ANGPT2 inhibitors in different diseases? 10/25/2016

Yes, there are several ongoing clinical trials investigating the use of ANGPT2 inhibitors in various diseases. These trials assess the safety, efficacy, and optimal dosing of ANGPT2 inhibitors either as monotherapy or in combination with other treatments. Some of the diseases being studied include solid tumors, diabetic macular edema, acute myeloid leukemia, and idiopathic pulmonary fibrosis, among others. These trials aim to determine the potential of ANGPT2 inhibitors as a therapeutic option in these diseases.

How do ANGPT2 inhibitors compare to other anti-angiogenic therapies? 08/25/2016

ANGPT2 inhibitors function as anti-angiogenic agents by blocking the activation of ANGPT2 and its interaction with the Tie2 receptor. Compared to other anti-angiogenic therapies, such as VEGF inhibitors, ANGPT2 inhibitors target a different pathway involved in angiogenesis regulation.

Where is ANGPT2 produced? 04/19/2016

ANGPT2 is produced by various cell types, including endothelial cells, immune cells, and certain cancer cells. Its production can be induced by different stimuli, such as hypoxia, inflammation, and growth factors.

Customer Reviews (5)

Write a review

    The ANGPT2 protein offers exceptional quality that meets the rigorous demands of experimental research. -


      Whether studying angiopoietin signaling pathways, vascular remodeling, or endothelial cell biology, the ANGPT2 protein is an invaluable tool for researchers. -


        What sets the ANGPT2 protein apart is not only its outstanding quality but also the excellent technical support provided by the manufacturer. -


          the ANGPT2 protein's versatility extends beyond its proven usefulness in in vitro experiments. -


            Its purity, consistency, and reliable performance make it a top choice for a wide range of applications. -

            Ask a Question for All ANGPT2 Products

            Required fields are marked with *

            My Review for All ANGPT2 Products

            Required fields are marked with *


            Inquiry Basket


            Stay Updated on the
            Latest Bioscience Trends

            Copyright © 2023 Creative BioMart. All Rights Reserved.

            Terms and Conditions        Privacy Policy